Laprophan’s acquisition of Amanys Pharma’s operations in Sub-Saharan Africa

Lead party: Laprophan S.A (lead investor/buyer)Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed). Target: Amanys Pharma (private company) · Sector: Healthcare, Pharmaceuticals · Countries of operation: Morocco Transaction type: Merger/Acquisition(M&A), Exit · Asset class: Private Equity, Corporate Transactions · Strategy: Bolt-On · Fund: SPE Africa Industrialisation Fund I Lead investor/buyer:…


Lead party: Laprophan S.A (lead investor/buyer)

Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).

Target: Amanys Pharma (private company) · Sector: Healthcare, Pharmaceuticals · Countries of operation: Morocco

Transaction type: Merger/Acquisition(M&A), Exit · Asset class: Private Equity, Corporate Transactions · Strategy: Bolt-On · Fund: SPE Africa Industrialisation Fund I

Lead investor/buyer: Laprophan S.A · Investors/buyers: Laprophan S.A · Sellers: SPE Capital Partners, Proparco

Legal advisers: not identified in the source record.

Source: announced 11 November 2023. Original announcement: spe-capital.com.